﻿<?xml version="1.0" encoding="utf-8"?><rss version="2.0"><channel><title>Silicon Investor - Gum Tech (GUMM)</title><copyright>Copyright © 2026 Knight Sac Media.  All rights reserved.</copyright><link>https://www.siliconinvestor.com/subject.aspx?subjectid=25049</link><description>
Gum Tech International (Nasdaq: GUMM)  The Company develops and manufactures specialty chewing gum products for branded and private label customers, as well as products marketed under the Gum Tech brand. The products contain vitamins, herbals and/or active drug ingredients. Gum Tech currently targets four market segments: oral care, smoking cessation, dietary supplement, and over-the-counter (OTC) drug.   5.6 million Float But it will behave like it has 1.6 million float because ~4 million of the float is held by long term holders who have extremely high price targets in the long term and have no plans to sell.  The long term share holders have removed their shares from being able to be shorted.    Each time the effective float of 1.6m is recycled the support level rises. As the effective float is recycled there will be shareholders who will simply not sell.  Which means the effective float decreases while demand increases.  Regards, S.W.</description><image><url>https://www.siliconinvestor.com/images/Logo380x132.png</url><title>SI - Gum Tech (GUMM)</title><link>https://www.siliconinvestor.com/subject.aspx?subjectid=25049</link><width>380</width><height>132</height></image><ttl>10</ttl><item><title>[StockDung] Inventor Of Zicam Gets 3 Years Probation For Unapproved Bird Flu Remedy  April 2...</title><author>StockDung</author><description>&lt;span id="intelliTXT"&gt;Inventor Of Zicam Gets 3 Years Probation For Unapproved Bird Flu Remedy  April 26, 2012 12:46 PM  &lt;br&gt;  &lt;br&gt;&lt;b&gt;LOS ANGELES (CBS) —&lt;/b&gt; The man who invented Zicam was sentenced Thursday to three years of probation for illegally marketing an unapproved drug he claimed could prevent and treat bird flu.&lt;br&gt;&lt;br&gt;  &lt;br&gt;  Charles B. Hensley, 58, of Redondo Beach, was indicted last year on a dozen felony charges related to sales of an influenza-treatment product called Vira 38 that did not have U.S. Food and Drug Administration approval.&lt;br&gt;&lt;br&gt;  As part of an agreement with prosecutors, Hensley pleaded guilty to one of the charges, Assistant U.S. Attorney Pio S. Kim said.&lt;br&gt;&lt;br&gt;  Hensley was ordered to serve 400 hours of community service and pay a $5,000 fine, Kim said.&lt;br&gt;&lt;br&gt;  Hensley was arrested last June by members of the Southern California Import Task Force, which consists of FDA and United States Postal Service agents and Los Angeles Police investigators.&lt;br&gt;&lt;br&gt;  Prosecutors say Hensley operated PRB Pharmaceuticals Inc., which marketed Vira 38 as an influenza medication in Hong Kong.&lt;br&gt;&lt;br&gt;  When marketing efforts failed, in part because of the lack of clinical data demonstrating the product’s usefulness, Hensley promoted Vira 38 as a medication to fight the H5N1 virus, which causes bird flu, according to the indictment.&lt;br&gt;&lt;br&gt;  While Hensley touted Vira 38 as a cure for bird flu, the product had not been approved by the FDA, according to the U.S. Attorney’s Office&lt;/span&gt;</description><link>https://www.siliconinvestor.com/readmsg.aspx?msgid=28127475</link><pubDate>5/6/2012 8:31:15 AM</pubDate></item></channel></rss>